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Abstract
Background—Intracoronary (IC) delivery of cardiosphere-derived cells (CDCs) has been 
demonstrated to be safe and effective in porcine and human chronic myocardial infarction (MI). 
However, IC delivery of CDCs after reperfusion in acute MI has never been assessed in a 
clinically-relevant large animal model. We tested CDCs as adjunctive therapy to reperfusion in a 
porcine model of MI.
Methods and Results—First, escalating doses (5, 7.5 and 10 million [M] cells) of allogeneic 
CDCs (allo-CDCs) were administered IC 30 minutes after reperfusion. Forty-eight hours later, left 
ventriculography (LVG) was performed and animals sacrificed to measure area at risk (AAR), 
infarct size (IS) and/ or microvascular obstruction (MVO). Secondly, identical endpoints were 
measured in a pivotal study of mini-pigs (n=14) that received 8.5-9M allo-CDCs, placebo solution 
or sham. Multiple indicators of cardioprotection were observed with 7.5M and 10M allo-CDCs, 
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but not 5M CDCs, relative to control. In the pivotal study, IS, MVO, cardiomyocyte apoptosis and 
adverse LV remodeling were all smaller in the CDC group than in sham or placebo groups. In 
addition, serum troponin I level at 24 hours was lower after CDC infusion than that in the placebo 
or sham groups, consistent with the histologically-demonstrated reduction in IS.
Conclusions—IC delivery of allo-CDCs is safe, feasible and effective in cardioprotection, 
reducing IS, preventing MVO and attenuating adverse acute remodeling. This novel 
cardioprotective effect, which we call “cellular postconditioning”, differs from previous strategies 
to reduce IS in that it works even when initiated with significant delay after reflow.
Keywords
allogeneic transplantation; cardiosphere-derived cells; cardioprotective effect; microvascular 
obstruction
Percutaneous coronary intervention (PCI) has become standard therapy worldwide for 
patients with acute myocardial infarction (AMI), not only reducing short-term adverse 
cardiac events but also improving long-term clinical outcome.1 Nevertheless, many AMI 
patients progress to HF even with best current therapy. Adverse left ventricular (LV) 
remodeling after AMI is a precursor to the development of overt HF and is an important 
predictor of mortality.2, 3 Prominent among the factors that underlie adverse remodeling is 
microvascular obstruction (MVO) after reperfusion,4, 5 a state of myocardial tissue 
hypoperfusion despite patent epicardial coronary arteries. Severe MVO may lead to “no-
reflow”, which is an independent predictor of adverse clinical outcome after AMI5, 6, 7. 
Numerous strategies have been tested to reduce infarct size (IS), but, once reflow has 
occurred, nothing appears to work. All successful pharmacologic strategies must be applied 
prior to reperfusion.8 Ischemic postconditioning (created by cyclical intracoronary balloon 
inflations) requires immediate manipulation of flow at the time of reperfusion, with loss of 
benefit if there is any significant delay.9, 10
Cell therapy has the potential to revise the paradigm, but little is known about the utility 
and/or risks of intracoronary cell administration soon after (i.e., within 30 min of) 
reperfusion. No clinical data are available; most cell therapy clinical trials have infused cells 
1-14 days post-AMI. By that time, cardiomyocytes at risk are already dead11, so that there is 
limited potential (if any) for myocardial salvage. Given the delays intrinsic to autologous 
tissue harvesting and cell processing, applications in the acute reperfusion phase will require 
allogeneic (off-the-shelf donor-derived) products. Preclinical studies of acutely-administered 
allogeneic mesenchymal stem cells (MSCs)12, 13, 14 or their precursors15 have yielded 
variable results. Although heart-derived stem cells have been tested in both large animals 
and humans in chronic ischemic settings,16, 17 the only studies in an acute ischemia/
reperfusion model were in rats,18, 19 where structural and functional outcomes were 
improved dramatically by the intracoronary infusion of cardiosphere-derived cells (CDCs) 
20 min post-AMI. However, the 3-week endpoint in those studies made it impossible to 
separate cardioprotection from regeneration.20
We sought to determine whether early infusion of allogeneic CDCs during reperfusion leads 
to myocardial protection in a clinically-relevant large-animal model. To avoid possible 
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ischemic postconditioning due to balloon inflations, and to mimic clinical reality, the 
initiation of therapy was delayed until 30 min post-reperfusion. We used a 48-hour endpoint 
in order to assess acute cardioprotection without the confounding effects of tissue 
regeneration, which may contribute to the final outcome of longer-term studies.20
Methods
For detailed methods please see the Online Supplement. All animal studies were performed 
with approval from the Institutional Animal Care and Use Committee of the Cedars-Sinai 
Health System. Three separate experimental protocols were performed, as depicted 
schematically in Figure 1 and in Supplementary Figure 1A. A total of 15 Yucatan mini-pigs 
were studied in a dose-escalation study (Figure 1A); 14 completed the pivotal study (Figure 
1B); and 6 pigs were dedicated to the measurement of cell engraftment (Supplementary 
Figure 1B). One Sinclair mini-pig (#0111) served as the donor for allogeneic heart-derived 
cells.
Cell culture
Allogeneic CDCs were grown from a freshly-explanted heart obtained from one male 
Sinclair mini-pig.
Myocardial infarct creation and CDC infusion
AMIs were created in adult Yucatan mini-pigs by inflation of an angioplasty balloon 
(TREK® OTW 2-3mm, Abbott Vascular, Santa Clara, CA) in the mid-left anterior 
descending artery (LAD) (distal to the 1st diagonal branch) for 1.5 h. Two studies were 
performed contemporaneously, involving a total of 39 minipigs: a dose-escalation study, and 
a pivotal study. Because of acute reperfusion-related mortality (n=4) or technical reasons 
detailed in the Results (n=6), 10 animals failed to complete the protocol.
Fifteen mini-pigs completed the dose-escalation study. Allogeneic CDCs (5, 7.5 and 10M 
cells; n=5 pigs per dose) were formulated, frozen and count-verified just prior to 
intracoronary infusion, which was performed 30 minutes post-reperfusion via an over-the-
wire balloon catheter, placed in the mid-LAD. From the dose-escalation cell counts, post-
thaw cell recoveries were 69.6 ± 1.5% and cell viability 90.7 ± 0.4% (n=7). The CDCs were 
administered in 3 equally-divided cycles of balloon inflation separated by 3 min of deflation 
(Figure 1A).16
Fourteen mini-pigs completed the pivotal study and were randomized to receive CDCs (n=4, 
with the cell infusion procedure as in the dose-escalation study), placebo (n=5) or sham 
(n=5; balloon placement in the LAD but without inflations, to exclude possible confounding 
effects related to ischemic post-conditioning). The latter two groups, which had similar 
distributions and medians, were statistically indistinguishable (p=0.11 to 0.59 in all of 
histological and functional indicators) and thus were pooled as controls for the dosing study. 
The pivotal study was designed to mimic a clinical situation in which preformulated bags of 
CDCs containing a nominal dose of 12.5M CDCs were frozen and thawed for 
administration, without cell counting prior to infusion; based on the post-thaw cell recovery 
data in the dose-escalation study, actual delivered total cell dosage was estimated at ∼8.7 M.
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To measure global LV function and volumes, left ventriculography (LVG) was performed 
before infusion and prior to sacrifice on day 2 using a pigtail catheter inserted retrogradely 
into the LV, with imaging in the 40° left anterior oblique projection (30 frames per second) 
using non-ionic contrast (27∼30 ml/ 3 sec). Left ventricular volumes were indexed to body 
surface area (BSA), calculated as per the formula (BSA= 0.121 * BW kg ^ 0.575).21
Safety evaluation (coronary flow and arrhythmia)
Coronary flow was evaluated utilizing Thrombolysis In Myocardial Infarction (TIMI) and 
corrected TIMI frame count grading systems. ECGs were recorded before induction of AMI, 
before CDC/vehicle infusion, immediately after CDC/vehicle infusion, 1 hour after CDC/
vehicle infusion (only in pivotal study) and prior to sacrifice to monitor for arrhythmias. In 
addition, ECGs were continuously monitored during intracoronary infusion and 1 hour post-
intervention for arrhythmias.
Histopathological evaluation
Two days after CDC or vehicle infusion, mini-pigs underwent median sternotomy and direct 
injection into the left atrium of dyes (Gentian Violet and Thioflavin T) to assess area at risk 
(AAR) and MVO. Then, mini-pigs were euthanized and the hearts explanted and sectioned 
into 1 cm thick short-axis slices to measure AAR, infarct size (IS) and MVO. Each slice was 
imaged digitally; IS and MVO areas were determined by manual tracing by a researcher 
blinded to treatment allocation. The fraction of the AAR within the total area was equated 
with its weight percent of the total weight of LV. MVO and IS were expressed as the weight 
percent of AAR.
Hemorrhage in the heart was investigated by hematoxylin and eosin staining of myocardial 
samples (fixed in 10% formalin, paraffin-embedded) obtained from the infarct, border and 
remote myocardium; analysis was performed by an experienced cardiac pathologist (DL) 
blinded to treatment allocation with an arbitrary scoring system (graded as none, mild, 
moderate or severe utilizing 0, 1, 2 and 3, respectively). To measure apoptotic 
cardiomyocytes, 8 μm sections from myocardial samples (fixed in 10% formalin, paraffin-
embedded) obtained from the infarct, border and remote zones underwent immunostaining 
for TUNEL (Roche 12156792910), α-sarcomeric actinin (ab9465 Abcam) and wheat-germ 
agglutinin (Invitrogen) (to visualize cell borders). Vascular density was quantified in pigs 
sacrificed 48 hours post reperfusion. A total of 3 to 5 sections obtained from the border 
zones were evaluated per heart with immunostaining for Isolectin (Invitrogen I21411) and 
α-smooth muscle actin (ab5694 abcam). Alexa Fluor-conjugated secondary antibodies 
(Molecular Probes) were used and counterstained for DAPI (Molecular probes). Sections 
were imaged using a confocal laser scan microscope (Leica Microsystems) and images were 
processed by Leica Application Suite software. The border zone was defined as the region at 
the edges of the scar (comprising areas of both viable and scarred myocardium).
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In the pivotal study, blood draws were performed 24 hours after CDC or vehicle infusion 
and prior to sacrifice (48 hours) to measure serum troponin I (TnI) as a marker of cardiac 
injury.
Engraftment study
Engraftment was measured (see Supplemental Figure 1A) as described.22 Luciferase-labeled 
CDCs were delivered via intracoronary infusion (n=6) 15 minutes post-reperfusion. Animals 
were sacrificed 15 minutes (n=3) or 48 hours (n=3) later and tissues were taken for 
luciferase measurement.
Statistical Analysis
Pooled data are expressed as box plots. Mann-Whitney U test was used for comparisons 
between 2 independent groups. Multiple groups were compared using Kruskal-Wallis test 
with Bonferroni post-hoc testing. Dynamite plot data are expressed as mean ± standard error 
of the mean. p < 0.05 was considered statistically significant.
Results
Adverse events and mortality
In the dose-escalation study (Supplementary Table 1), 1 animal out of the 18 (6%) died due 
to cardiogenic shock immediately after LVG post-reperfusion. Two pigs were excluded due 
to technical failure or incomplete dye study. There was no further mortality (0%), nor were 
any adverse events noted during the infusion procedure in either group. In the pivotal study, 
3/21 animals (14%) died during creation of MI due to ventricular arrhythmia; 3 pigs were 
excluded due to technical failure of MI creation or incomplete dye study. One pig was 
excluded due to incidentally-discovered hypertrophic cardiomyopathy at necropsy. Thus, a 
total of 14 pigs completed the pivotal study. There was no further mortality within the 
protocol (0%), nor were there any other adverse events (Supplementary Table 2).
Dose-Escalation Study
Functional and histological benefits of CDC infusion with optimal dose—To 
assess differences of treatment effects with escalating doses of allogeneic CDCs, we 
measured cardiac function and volumes by LVG. Representative ventriculograms 48 hours 
post-CDC treatment show amelioration of LV anterior wall motion compared with control, 
especially in the 7.5M pig (yellow arrows, Fig. 2A). Although the changes in the ejection 
fraction from baseline to 48 hours post CDC infusion were not significantly different among 
groups (Fig. 2B), mini-pigs in control and 5M groups underwent progressive LV dilatation 
(both at end-diastole [Fig. 2C] and end–systole [Fig. 2D]); the change in LVEDVI was 
significantly attenuated in the pigs that received 7.5M (Fig. 2C). In addition, we evaluated 
AAR, IS and MVO by dye study 48 hrs post-infusion. Although AAR in the 4 groups was 
comparable, IS and MVO (as a % of AAR) were smaller (7.5M) or strongly tended to be 
smaller (10M) than in the control or 5M groups (Fig. 2 E, F and G).
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Pathological assessment and cytoprotective effect of CDCs with optimal 
dosage—The extent of intramyocardial hemorrhage was indistinguishable in all groups 
(Supplementary Fig.2A, B). In contrast, CDC infusion blunted apoptosis as revealed by 
TUNEL staining (Fig 3A). The number of TUNEL-positive cardiomyocytes in the border 
zone was lower in all CDC groups than in control (p=0.002; Fig. 3B, left panel), a pattern 
repeated, albeit with less significance (p=0,052), in the ischemic zone (Fig 3B, right panel).
As for coronary flow evaluation, absolute corrected TIMI frame counts (cTFC) post-
infusion were different in the 4 groups (p<0.05, Supplementary Table 1), with significant 
pairwise differences between control and 10M, but no differences among control, 5M or 
7.5M groups (Supplementary Fig. 3).
Overall, although there is a tendency for 10M to be worse than 7.5M, both 7.5M and 10M 
appear to be better than control or 5M in terms of functional, histological and safety 
concern. We conclude that 7.5-10M is the optimal therapeutic dosage range.
Pivotal Study
Having established a target dosage range of 7.5-10M CDCs, we performed a pivotal 
preclinical study with animals randomized to placebo, sham or CDC groups. The CDC 
group mimicked the clinical situation in which a preformulated bag is acutely thawed for 
infusion at the site of reperfusion. It is clinically-unrealistic to perform cell counting prior to 
product release in the AMI setting, so that infusion bags filled with 12.5M CDCs were used, 
without onsite cell counting and recognizing that some of the cell product would be retained 
in the dead space of the bags and tubing. From the cell count findings in the dose-escalation 
study, actual delivered cell dosage was estimated at ∼8.7M, well within the desired 
therapeutic range of 7.5-10M.
Histological efficacy of intracoronary infusion of CDCs as adjunctive therapy to 
reperfusion
To assess the acute benefit of allogeneic CDCs, we evaluated histological efficacy of CDCs 
by dye study at 48 hours. Fig. 4A shows representative slices stained with gentian violet to 
delineate AAR, and TTC (2,3,5-triphenyl tetrazolium chloride) to quantify IS.23 The 
infarcted zone (white/ yellow) within the AAR (brick-red) is visibly smaller than that of 
sham or placebo. The AAR/LV (as a % of the LV) was similar among all three groups, 
indicating comparable degrees of initial injury (Fig. 4B). IS (as a % of AAR) was smaller in 
the CDC group (59.7%, p<0.05 vs sham and placebo) compared with sham (81.0%) or 
placebo (80.3%; Fig. 4C). In addition, IS (as a % of the LV) was also smaller in the CDC 
group (12.5%, p<0.05 vs sham and placebo) than in sham (19.9%) or placebo (18.5%) 
groups (Fig. 4D).
We also evaluated MVO in the pivotal study. Fig. 4E shows ultraviolet epifluorescent 
images of representative slices stained with thioflavin T; here, the MVO area appears dark 
as it has not taken up the infused thioflavin and thus is non-fluorescent. MVO area is 
distinctly smaller in the CDC-treated pig than in sham or placebo, as verified by the pooled 
data in Fig. 4F.
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Functional efficacy in the acute phase of intracoronary infusion of allogeneic CDCs
We assessed the acute treatment effects of allogeneic CDCs on LV function and volumes by 
LVG. Although the change of ejection fraction (Fig. 5A) between baseline and 48 hours 
post-intervention was similar in all groups, mini-pigs in sham and placebo groups underwent 
progressive LV dilatation (Fig. 5B,C), which was attenuated in CDC-treated pigs.
Safety evaluation of intracoronary infusion of CDCs
Consistent with the structural evidence of reduced myocardial injury (Fig. 4), CDC 
treatment decreased serum troponin I level measured 24 hours post-MI (Fig. 5D). These data 
support the conclusion that CDCs exert a cardioprotective effect, even when cell 
administration is delayed to 30 min after reperfusion.
Pathological assessment and cytoprotective effect in pivotal study
The extent of intramyocardial hemorrhage was comparable in the three experimental groups 
(Supplementary Fig. 4A, B). We also quantified apoptosis in the three groups by staining 
border and infarct zone samples for TUNEL (Fig 6A). Consistent with the results of the dose 
escalation study, the percentages of TUNEL-positive myocytes in the border (49.5%) was 
lower in CDC-treated hearts than in sham (68.8%) or placebo (64.3%) (Fig 6B, upper 
panel). Here we additionally see unequivocal benefit in the infarct zone (Fig 6B, lower 
panel).
Measurement of CDC engraftment by luciferase
Cardiac engraftment of CDCs decreased from 39.9±9.6% (n=3) at 15 minutes to 3.7±1.6% 
(n=3) at 48 hours. There was a significant difference in engraftment at the two time points 
(Supplementary Figure 1B).
Assessment of vascularization
We analyzed vessel density in border zone samples by immunostaining in dose-escalation 
and pivotal studies (Supplementary Fig 5A, B). Quantification of vessel density did not 
reveal any significant differences among groups.
Discussion
Early and successful myocardial reperfusion with PCI is the most effective strategy for 
AMI.24, 25 However, reperfusion itself has the potential to aggravate injury, which may in 
part explain why the incidence of HF after AMI approaches 25%.26 Here we have 
demonstrated a novel benefit of infused CDCs administered 30 min after reperfusion: such 
treatment decreased IS and MVO in pigs with AMI. Our findings are notable for two 
reasons: first, CDCs work despite having been administered relatively late after reperfusion. 
No other cardioprotective modality has successfully reduced IS without pretreatment 
(ischemic or pharmacologic preconditioning) and/or immediate intervention upon reopening 
the affected artery (ischemic postconditioning). Secondly, our study design, with 48-hour 
structural and functional endpoints, guarantees that we are studying acute cardioprotection; 
otherwise it is impossible to exclude a partial or dominant contribution from longer-term 
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regenerative effects of the cells, which are evident only weeks after treatment.20 Given the 
novelty of the phenomenon described here, we call it “cellular postconditioning”.
The influence of post-conditioning on reperfusion injury
Ischemic “post-conditioning”, described by Zhao et al.27, is a cardioprotective phenomenon 
which can be recruited by applying intermittent cycles of ischemia immediately after 
reperfusion. There is some inconsistency in the literature as to how long a delay after 
reperfusion can be imposed while retaining the benefits of ischemic postconditioning, with 
most studies claiming rapid evanescence (<10 min) 9, 10, but one showing that delays of up 
to 30 min may be possible.28 To see whether ischemic postconditioning might have 
influenced our own results, we compared the placebo group (where three cycles of stop-flow 
ischemia were applied without cell infusion) to the sham group, which simply had a catheter 
placed in the LAD without intermittent balloon inflations. Results in the two groups were 
indistinguishable, ruling out a contributory role for ischemic postconditioning in our 
protocol. Thus, the cardioprotective effects of CDCs infused at 30 min are distinct from 
those of ischemic postconditioning. Not only is the trigger different (cells vs ischemia), but 
also the window of treatment opportunity is longer. Such a delay is consistent with clinical 
reality: when a patient presents with AMI, the immediate focus is on prompt recanalization 
of the occluded vessel. Only after patency has been re-established and a stent deployed will 
the typical clinician consider adjunctive therapy; the allowance of 30 min to initiate infusion 
accomodates decision to treat, product thawing and technical preparation for administration.
The feasibility and safety of intracoronary infusion of CDCs in AMI
In addition to the considerations above, translation will be facilitated by the fact that we 
used standard clinical equipment and intracoronary infusion for cell transplantation. 
Intracoronary infusion can be performed in a minimally-invasive manner, and has been 
safely used in numerous preclinical studies and clinical trials17, 18, 22, 29, 30 Some previous 
large-animal studies have questioned the safety of intracoronary infusion of stem cells post-
MI, with decreased coronary flow and elevation of cardiac enzymes attributed to 
microvascular plugging.12, 13, 14, 31 Houtgraaf et al. had more favorable results after careful 
attention to cell dosage, size and infusion rate.15 In terms of cell dosage, we have validated 
the safety of 12.5M intracoronary CDCs in pigs with chronic ischemic cardiomyopathy, and 
25M CDCs administered to post-MI patients in the CADUCEUS trial, without 
complications such as microembolization.18, 22 Cell dosage must be carefully validated in 
the acute phase of reperfusion post-MI, given the presence of infarct-related microvascular 
injury.32 As for cell size, although it is reported that the average diameter of mesenchymal 
stem cells (MSC) is 30-50 μm33, CDCs are ∼20μm in diameter.22 In addition, previous 
studies demonstrated micro-infarction or slow-flow phenomena at high infusion rates and/or 
high cell doses (e.g., 50M cells at a rate of 1.5M cells/min).12, 14 On the other hand, 
Houtgraaf et al. found that slow infusion of mesenchymal progenitor cells (MPCs; 0.5M 
cells/min) enabled intracoronary infusion of 50M cells without compromise of coronary 
flow.15 Here, we infused relatively low cell numbers at rates of 0.8-1.6M/min following 
reperfusion; 7.5M-10M CDCs at rates of 1.25M-1.6M cells/min were well-tolerated and 
therapeutically active, in general agreement with Houtgraaf et al.15 Our studies differ in that 
we delayed cell infusion until 30 min after reflow (Houtgraaf et al.15 began infusion at 15 
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min of reflow) and in the timing of IS quantification: we focused on 48-hour endpoints, 
while Houtgraaf et al.15 quantified IS only at 8 weeks, at which time longer-term 
regenerative effects may cloud the evaluation of cardioprotection.20
Potential mechanism of benefit in CDC-treated hearts
In the vast majority of experimental studies, the number of differentiated myocytes derived 
from transplanted stem cells is too small to account for the observed improvements in 
cardiac function.34 Thus, the prevailing concept of stem cell efficacy has shifted towards the 
‘paracrine hypothesis’, according to which the transplanted cells are proposed to produce 
soluble factors that are beneficial to the infarcted heart.35 Indeed, skeletal myoblasts,36 
bone-marrow (BM) derived cells37 and cardiac-derived cells38 produce and secrete a broad 
variety of cytokines. In small comparative studies, CDCs outperformed MSCs in vitro39 and 
in vivo.40 In a head-to-head comparison of four different cell types (CDCs, BM-derived 
mononuclear cells, BM-derived MSCs and adipose-derived MSCs) in the same animal 
model in the same laboratory, CDCs emerged as superior in terms of paracrine factor 
secretion, angiogenesis, cardiomyogenic differentiation, ischemic tissue preservation, anti-
remodeling effects and functional benefit post-MI.41
Potential cardioprotective effects of paracrine factors include anti-apoptotic effects on 
resident myocytes, upregulation of angiogenesis, modulation of inflammatory processes 
resulting in better infarct healing, improvements of cardiac metabolism and contractility, 
promotion of cardiomyocyte cell cycle re-entry, and induction of secondary humoral effects 
in the host tissue.42, 43 Here, we observed histological benefits including reduction of IS, 
MVO and apoptotic cardiomyocytes only 48 hours post cell transplantation, which is 
consistent with paracrine effects but not differentiation of transplanted cells into 
cardiomyocytes or vessels, as demonstrated in Supplementary Figures 1 and 5. Beyond these 
considerations, however, the present study provides no insight into the detailed mechanisms 
of benefit of cellular postconditioning.
Limitations
This study has several limitations. First, this model is one of iatrogenic AMI caused by 
balloon occlusion. The pathophysiological situation differs from acute coronary syndrome 
with regard to influence of micro-embolization derived from atherosclerotic plaque or 
thrombus. Also, the well-defined duration of ischemia here differs from the clinical 
situation, which is much more heterogeneous. Second, we infused allogeneic CDCs in this 
study, but did not look for a potential immune response given the short-term nature of the 
endpoints. However, allogeneic heart-derived cells have been transplanted without eliciting 
deleterious immune reactions in previous reports.16, 44, 45 Although “off-the-shelf” 
allogeneic products are clearly necessary for the infusion of cells immediately after PCI, we 
need to test the safety concerns of allogeneic cells in longer-term experiments.
Conclusions
We demonstrate a cardioprotective effect of CDCs after reperfusion utilizing a large animal 
model and strategies that are compatible with standard clinical practice. These results 
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motivate not only potential clinical exploration of acutely-administered CDCs in AMI, but 
also the further exploration of long-term efficacy and mechanism of benefit.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Study protocols
Dose-escalation study (A) and pivotal study (B). CDCs: cardiosphere-derived cells, LVG: 
left ventriculography, AMI: acute myocardial infarction, TnI: troponin I.
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Figure 2. Comparison of different doses of CDCs for assessment of functional and histological 
efficacy
Representative left ventriculograms at each dose of CDCs (A). Arrow indicates preserved 
wall motion in the border zone 48 hours post-intervention. Yellow lines indicate a contour of 
end-diastolic and -systolic left ventricular endocardial margins. Pooled change in LVEF (B), 
LVEDVI (C) and LVESVI (D) between baseline and two days post CDCs infusion with 
escalating dosage. Comparison of area at risk (E), infarct size (F), and MVO (as % of AAR) 
48 hours post-infusion.
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LVEDVI: left ventricular end-diastolic volume index; LVESVI: left ventricular end-systolic 
volume index. p value is the result of Kruskal-Wallis test., *: p<0.05 and **: p<0.01 
between two groups.
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Figure 3. Optimized doses of CDCs attenuate apoptosis
Comparison of apoptosis of cardiomyocytes assessed by TUNEL staining (A) and 
quantitative evaluation of TUNEL-positive cell number in border and infarct zones (B). 
WGA: wheat-germ agglutinin; α-SA; α-sarcomeric actinin. p value means the result of 
Kruskal-Wallis test., *; p<0.05 between two groups.
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Figure 4. Allogeneic CDCs attenuate infarct and no-reflow size
Representative transverse cardiac slices stained with Gentian violet and TTC (A). Area at 
risk (as % of LV) (B), infarct size (as % of area at risk) (C) and infarct size (as % of LV) (D) 
at 48 hours post-intervention. Representative transverse cardiac slices stained with 
Thioflavin-T under ultraviolet light (E). No-reflow area (as % of area at risk) 48 hours post-
intervention (F). AAR: area at risk; IS: infarct size; TTC: 2,3,5-triphenyl tetrazolium 
chloride; NR: no-reflow. p value is the result of Kruskal-Wallis test., *: p<0.05between two 
groups.
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Figure 5. Functional efficacy and safety assessment after intracoronary infusion of allogeneic 
CDCs
Comparison of changes in LV ejection fraction (A), end-diastolic volume index (B) and end-
systolic volume index (C) in sham, placebo and CDCs groups. D: Serum troponin I levels at 
24 and 48 hrs post-intervention LVEF: left ventricular ejection fraction; LVEDVI: left 
ventricular end-diastolic volume index; LVESVI: left ventricular end-systolic volume index. 
p value is the result of Kruskal-Wallis test (0.03 at 24 hrs and 0.24 at 48 hrs). *: p<0.05 
between two groups.
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Figure 6. Allogeneic CDCs decreased apoptosis of cardiomyocytes assessed by TUNEL staining
Comparison of apoptosis of cardiomyocytes assessed by TUNEL staining (A) and 
quantitative evaluation of TUNEL-positive cell number in border and infarct zones (B). 
WGA: wheat-germ agglutinin; α-SA: α-sarcomeric actinin. p value is the result of Kruskal-
Wallis test., *: p<0.05 between two groups.
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